Program
At a Glance and Detailed versions of the ISLH 2010 program are listed below. Click here to download the ISLH 2010 Announcement (1 mb PDF).
At A Glance
|
Monday
|
Tuesday
|
Wednesday
|
|
|
Breakfast Sessions
7:15 – 8:30 AM
|
Business Meeting
8:00 - 8:45 AM
|
Breakfast Sessions
7:15 – 8:30 AM
|
Plenary Lectures
Berend Houwen Lecture
9:30 – 1:00 PM
|
Session 3
Flow Cytometry 1 – Clinical
9:00 – 12:00 PM
|
Session 4
Point of Care (Haemostasis)
9:00 – 12:00 PM
|
Session 7
New Diagnostic Technologies
9:00 – 12:00 PM
|
Session 8
Point of Care
(Cellular Analysis)
9:00 – 12:00 PM
|
|
|
|
|
|
Session 1
Morphology- T/NK-Cell and Mast Cell Malignancies
3:00 –6:00 PM
|
Session 2
Haemostasis
3:00 – 6:00 PM
|
Session 5
Flow Cytometry 2 - Technology and Software Developments
2:00 – 5:00 PM
|
Session 6
Oral Anticoagulant Therapy
2:00 – 5:00 PM
|
Session 9
International Council for Standardization in Haematology (ICSH) Forum
2:00 - 5:00 PM
|
Session 10
Haemoglobinopathies
2:00 - 5:00 PM
|
Opening Reception and Posters
6:00 – 8:00 PM
|
Meeting Banquet
7:00 – 11:00 PM
|
|
Program Details
|
AM: Plenary Lectures
Kathryn Foucar (USA) - Diagnosing myelodysplastic/ myeloproliferative diseases: Laboratory testing strategies to exclude other disorders.
Swee Lay Thein (UK) - Genotypic modifiers of the phenotype of haemoglobinopathies.
Trevor Baglin (UK) - Utilising the laboratory to predict recurrent venous thrombosis: from first to second generation thrombophilia tests.
Alberto Orfao (Spain) - Berend Houwen Memorial Lecture - Flow cytometry immunophenotyping in the diagnosis, classification and monitoring of haematological malignancies: from the past to the future.
PM: I. Morphology- T/NK-Cell and Mast Cell Malignancies
Kathryn Foucar (USA) - T-cell disorders I – Lymphomas
Wendy Erber (UK) - T-cell disorders II – Leukaemias
Gianpietro Semenzato (Italy) - NK-cell disorders
Luis Escribano (Spain) - Clinical and laboratory diagnosis of neoplastic mast cell disorders.
PM: II. Haemostasis
Bruce Furie (USA) - Thrombus formation in vivo.
Paula Bolton Maggs (UK) - Rare bleeding disorders: Are they under-diagnosed?
Paul Harrison (UK) - Will detection of microparticles have clinical utility?
Marcel Levi (Netherlands) - Disseminated intravascular coagulation: Which laboratory tests are most useful?
AM: III. Flow Cytometry 1 – Clinical
Juan Flores (Spain) - Towards standardization of multicolor flow cytometry immunophenotyping of haematological malignancies.
Ludovic Lhermitte (France) - Novel immunophenotypic approaches for the diagnostic classification of acute leukemias.
Paolo Lucio (Portugal) - Standardized eight color flow cytometry for classification and minimal residual disease follow-up of B lineage Non-Hodgkin lymphomas - the EuroFlow approach.
Jacques JM van Dongen (Netherlands) - Flow cytometry inmunobead assays for the identification of chromosomal translocations in acute leukemias.
AM: IV. Point of Care (Haemostasis)
Chris Gardiner (UK) - Point of careINR Testing: What monitors are currently available?
Dianne Kitchen (UK) - How should point of care international normalized ratio monitors be quality controlled?
Steve Kitchen (UK) - Agreement between laboratory and point of care international normalized ratio: What should we expect?
Alistair Nimmo (UK) - Haemostasis testing in the operating theatre.
|
PM: V. Flow Cytometry 2 - Technology and Software Developments
Alberto Orfao (Spain) - EuroFlow flow cytometry software tools for improving characterisation of haematological malignancies.
Andy Rawstron (UK) - The need for new approaches to the analysis of flow cytometry data .
Mike Keeney (Canada) - The Kaluza software for flow cytometry.
Tomas Kalina (Czech Republic) - Objective computational approach for phenotype analysis using probability binning.
PM: VI. Oral Anticoagulant Therapy
David Fitzmaurice (UK) - Patient self-testing and self-management of vitamin K antagonist therapy.
Jack Ansell (USA) - Managing vitamin K antagonist therapy: Patient self-management or traditional care?
Sam Machin (UK) - Warfarin therapy: What is the prognosis?
Chuck Eby (USA) - Pharmacogenetic and clinical factors to predict the dose of warfarin.
AM: VII. New Diagnostic Technologies
Ken Mills (UK) - Expression profiling and disease diagnosis.
Anthony Bench (UK) - New PCR techniques in the assessment of haematological malignancies.
Elizabeth Grimwade (UK) - Imaging flow cytometry.
John Reilly (UK) - Standardisation of molecular genetic testing.
AM: VIII. Point of Care (Cellular Analysis)
Cees van Berkel (UK) - Developments in blood count point-of-care testing.
Linda Sandhaus (USA) - Incorporation of point-of-care into clinical practice.
Barbara de la Salle (UK) - Point-of-care testing in clinical practice: Applications in the mental health setting.
Utkun Demirci (USA) - A new technology to count CD 4 lymphocytes without a flow cytometer or microscope with potential use in rual locations.
PM: IX. International Council for Standardization in Haematology (ICSH) Forum
Gini Zini (Italy) - Guideline on Schistocyte assessment.
Adrian Stephens (UK) - Update on haemoglobin A2/F methods and standards.
Anna Porwit (Sweden) - Standardization of Bone Marrow Immunohistochemistry.
Carol Briggs (UK) - Overview of ICSH activity.
PM: X. Haemoglobinopathies
Shirley Henderson (UK) - Laboratory diagnosis of alpha thalassemia.
John Old (UK) - DNA diagnosis of beta thalassemia.
Kees Harteveld (Netherlands) - New diagnostic techniques: Use of multiplex ligation-dependent probe amplification for deletion mutation detection.
Marina Kleenthous (Cyprus) - New molecular diagnostic approaches for non-invasive prenatal diagnosis using cell free fetal DNA.
|
Corporate Luncheons (Non-CME)
Monday 10 May
BD Biosciences - Improving Workflow with Sample Prep Automation
Luncheon session attendees will learn about automating the staining, lysing and fixing of cellular specimens for multicolor flow cytometry immunophenotyping. Equipment enhancements and protocols will be described.
Speakers:
Mark Herberger, Marketing Director
Nicole Ovadia, Senior Product Manager, Clinical Automation
Siemens - The Optimal use of Laboratory Parameters in Managing Oncology Patients.
Speakers:
Iron Deficient Erythropoiesis in Cancer - Pathogenesis, Diagnosis and Consequences
Professor M Nowrousian, West German Cancer Centre, Essen
Measurement of the Absolute Neutrophil Count using the ADVIA Haematology Analyser
Dr. K de Bruyn, Maasstad Ziekenhuis, Rotterdam
Tuesday 11 May
Sysmex UK LTD
Sysmex invites the audience to enjoy exciting scientific lectures on up-to-date topics in laboratory haematology served along with delicious food. Learn about the impact of the blood passport in anti-doping control and how experts evaluate the profiles. Get to know about the value of the Case Manager and how it can expand the role of the lab by supporting clinical decision making.
Speakers:
The blood passport: A sophisticated haematological tool has been very successful in anti-doping control.
Michael Ashenden, PhD
Director SIAB Research Consortium, Gold Coast, Australia
Canalising the data flood: The XE-5000 Case Manager combines laboratory data with clinical knowledge.
Julia Dittmann, PhD
Manager Medical & Scientific Services
Sysmex Europe GmbH, Norderstedt, Germany
Abbott - Recent Advances in Hematology Analysis
Luncheon attendees will hear about 2 different studies which expand the applications for CELL-DYN Sapphire. Additionally, attendees will receive an update on next generation Hematology platforms.
Speakers:
CD64 Testing on CELL-DYN Sapphire
Joan Cid, MD, PhD, Villarroel Hospital, Barcelona, Spain
Expanded RBC Parameters
Wouter van Solinge, PhD, University Medical Center, Utrecht, NL
Progress update on laser rastering in Hematology
Giacomo Vacca, PhD, Abbott Hematology
By Invitation Only. Please contact rick.gooch@abbott.com or your local Abbott representative for more information on attending this luncheon.
Wednesday 12 May
Beckman Coulter - HematoFlow & Cellular Population Data: New Parameters for Advanced Patient Care
Speakers:
HematoFlow Solutions
Dr. Olivier Pradier, University Hospital Erasme, Bruxelles, Belgium
Clinical Use and Utility of Cell Population Data and HematoFlow
Dr. Arnaud Jean and Pr. Marc Vasse, University Hospital, Rouen, France
Software and Algorithm Automation for HematoFlow
Chris Godefroy, Beckman Coulter Hematology Algorithm Development
To register for the Industry Luncheon (space is limited) and to view the abstracts
please visit: www.beckmancoulter.com/ISLH2010
Sebia - Hemoglobinopathies & Thalassemia: new diagnostic tools for laboratory facing a change of paradigm
Hemoglobinopathies are the most common, autosomal recessive disorder worldwide. Recent data indicate that about 7% of the world’s population is a healthy carrier of an haemoglobin disorder, and that over 300,000 children are born each year with the severe Hemoglobinopathies (World Bank 2006, report of a joint WHO-March of Dime meeting 2006) It is now recognized that these disorders are not particularly confined to endemic regions, but spread widely across the world through old and more recent massive migrations and thus constitute a severe global public health problem in endemic and non endemic immigration countries. These changes have challenged health professionals and policy-makers throughout the world in providing equitable access to quality services for the prevention and treatment of hemoglobin disorders. Primary prevention programs have been implemented in several European countries where carriers are routinely diagnosed in childhood, before marriage, in early pregnancy or at birth. Experience gained from these programs has shown that well organized primary prevention is welcome by the public, leading to a dramatic decrease in the incidence of affected children. The role of the General Practitioner is crucial in initiating prevention. The average GP in non-endemic countries is not used diagnose healthy carriers or to treat patients affected with the severe forms. On the other hand, the same GPs may have many carriers among their allochthonous clients that can be easily diagnosed at the laboratory level but only after a doctor has sent a blood sample for analysis. Basic carrier diagnosis of the haemoglobinopathies is based on separation and evaluation of the hemoglobin fractions. This has been performed, for many years, by means of electrophoresis, followed by manual quantification. Today, automatic methods such as HPLC or Capillary Electrophoresis analysis are the methods of choice in the modern laboratory. The last method in particular has been recently tailored by SEBIA, a company with long experience in protein electrophoresis, creating a state of the art dedicated device for haemoglobinopathies diagnostics. This to fulfill the growing worldwide demand for all different diagnostic application from new born screening programs to carrier or patient diagnostics in young adult, pregnant women and fetal material. With three lectures from leading experts in the field, SEBIA is introducing two new devices for newborn screening and adult diagnostics, offering a broad choice of multipurpose systems and methods, CAPILLARYS™ 2 Neonat Fast for newborn screening from dried blood spot, cord blood or packed red cells, and the versatile CAPILLARYS™ 2 Flex Piercing for adult testing from whole blood capped primary tubes, serum protein electrophoresis, Immunotyping and CDT. The aim of this luncheon session is to value the benefits of capillary electrophoresis technology for the screening of haemoglobinopathies disorders and to get an overview of its various applications
Moderator:
Dr. P. C. Giordano, Ph.D,
Aed Prof. Clinical biochemical molecular geneticist.
Human and Clinical Genetics department, Hemoglobinopathies Laboratory
Leiden University Medical Center
O&O Building, Einthovenweg 20- 2333 ZC, Leiden (The Netherlands)
Speakers:
James D. Hoyer, MD
Consultant
Director, Metabolic Laboratory
Division of Hematopathology
Mayo Clinic
Rochester, MN
US
Pr. Dr. Supan Fucharoen (to be confirmed)
Center for Research and Development of Medical Diagnostic Laboratories
Faculty of Associated Medical Sciences
Khon Kaen University
Khon Kaen
Thailand
Pr. Béatrice Gulbis, M.D., Ph.D
Department of Clinical Chemistry
Hôpital Erasme
Université Libre de Bruxelles
Bruxelles, Belgium
|
